L'Huillier Arnaud G, Meyer Benjamin, Andrey Diego O, Arm-Vernez Isabelle, Baggio Stephanie, Didierlaurent Arnaud, Eberhardt Christiane S, Eckerle Isabella, Grasset-Salomon Carole, Huttner Angela, Posfay-Barbe Klara M, Royo Irene Sabater, Pralong Jacques A, Vuilleumier Nicolas, Yerly Sabine, Siegrist Claire-Anne, Kaiser Laurent
Paediatric Infectious Diseases Unit, Department of Woman, Child and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, 6 rue Willy-Donze, 1211 Geneve 4, Switzerland; Laboratory of Virology, Department of Diagnostics, Geneva University Hospitals and Faculty of Medicine, 4 rue Gabrielle-Perret-Gentil, 1211 Geneve 4, Switzerland.
Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Centre Medical Universitaire, 1 rue Michel-Servet, 1211 Geneva, Switzerland.
Clin Microbiol Infect. 2021 Jan 20;27(5):784.e1-8. doi: 10.1016/j.cmi.2021.01.005.
To evaluate longitudinally the persistence of humoral immunity for up to 6 months in a cohort of hospital employees with mild coronavirus disease 2019 (COVID-19).
We measured anti-RBD (receptor binding domain of viral spike protein), anti-N (viral nucleoprotein) and neutralizing antibodies at 1, 3 and 6 months after mostly mild COVID-19 in 200 hospital workers using commercial ELISAs and a surrogate virus neutralization assay.
Antibodies specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) persisted in all participants for up to 6 months. Anti-RBD geometric mean concentrations (GMCs) progressively increased between months 1 (74.2 U/mL, 95%CI: 62.7-87.8), 3 (103.2 U/mL, 95%CI: 87.9-121.2; p < 0.001), and 6 (123.3 U/mL, 95%CI: 103.4-147.0; p < 0.001) in the whole cohort. Anti-N antibodies were detectable in >97% at all times. Neutralizing antibodies were detectable in 99.5% of participants (195/196) at 6 months post infection. Their GMC progressively decreased between months 1 (20.1 AU/mL, 95%CI: 16.9-24.0), 3 (15.2 AU/mL, 95%CI: 13.2-17.6; p < 0.001) and 6 (9.4 AU/mL, 95%CI: 7.7-11.4; p < 0.001). RBD-ACE2-inhibiting antibody titres and anti-RBD antibody concentrations strongly correlated at each timepoint (all r > 0.86, p < 0.001). Disease severity was associated with higher initial anti-RBD and RBD-ACE2-inhibiting antibody titres, but not with their kinetics.
Neutralizing antibodies persisted at 6 months in almost all participants, indicating more durability than initially feared. Anti-RBD antibodies persisted better and even increased over time, possibly related to the preferential detection of progressively higher-affinity antibodies.
纵向评估一组轻度2019冠状病毒病（COVID-19）医院员工长达6个月的体液免疫持久性。
我们使用商业酶联免疫吸附测定法（ELISA）和替代病毒中和试验，在200名医院工作人员发生大多为轻度的COVID-19后1、3和6个月测量抗RBD（病毒刺突蛋白受体结合域）、抗N（病毒核蛋白）和中和抗体。
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性抗体在所有参与者中持续存在长达6个月。在整个队列中，抗RBD几何平均浓度（GMC）在第1个月（74.2 U/mL，95%CI：62.7-87.8）、第3个月（103.2 U/mL，95%CI：87.9-121.2；p<0.001）和第6个月（123.3 U/mL，95%CI：103.4-147.0；p<0.001）之间逐渐增加。抗N抗体在所有时间点的检测率均>97%。在感染后6个月，99.5%的参与者（195/196）可检测到中和抗体。其GMC在第1个月（20.1 AU/mL，95%CI：16.9-24.0）、第3个月（15.2 AU/mL，95%CI：13.2-17.6；p<0.001）和第6个月（9.4 AU/mL，95%CI：7.7-11.4；p<0.001）之间逐渐下降。在每个时间点，RBD-ACE2抑制抗体滴度和抗RBD抗体浓度都高度相关（所有r>0.86，p<0.001）。疾病严重程度与较高的初始抗RBD和RBD-ACE2抑制抗体滴度相关，但与它们的动力学无关。
几乎所有参与者在6个月时仍存在中和抗体，表明其持久性比最初担心的更强。抗RBD抗体持久性更好，甚至随时间增加，这可能与逐渐检测到亲和力更高的抗体有关。
